A study found that AstraZeneca’s lung cancer treatment taggriso (ingredient name: osimertinib) showed significantly improved survival time compared to the existing standard treatment.
The results of this phase 3 clinical study (FLAURA China), published in the online edition of the journal’Targeted Oncology’ on the 5th, showed remarkably improved progression-free survival (PFS) and overall survival (OS) compared to standard treatment. It is consistent with the FLAURA research.
As a result of the study, the median progression-free value of the tagriso-treated group was 17.8 months, which was 8.0 months longer than 9.8 months in the standard treatment group (first generation EGFR-TKI), and the risk of death was reduced by 44%. The median overall survival period was 33.1 months, which was 7.4 months longer than the standard treatment group (25.7 months), and the risk of death was reduced by 15%.
Treatment duration was also higher in the Tagriso treatment group. The median duration of treatment in the Tagriso group was 20.0 months, which was 6.4 months longer than 13.6 months in the standard treatment group. At 3 years of dosing, only 8% of patients in the standard treatment group continued treatment, whereas in the Tagriso group, 20% continued treatment. At 2 and 3 years of treatment, the survival rates of the tagriso group were 64.3% and 38.6%, respectively, which was higher than that of the standard treatment group 54.2% and 32.6%.
The FLAURA China study is a clinical trial of the same protocol as the entire FLAURA clinical study, and is designed to allow cross-administration of Tagriso in patients with a T790M mutation in the case of disease progression in the standard treatment group. As a result of the analysis, 34% of patients in the standard treatment group allowed cross-administration of tagriso as a second-line treatment, and showed a prolonged survival of the first dose of tagriso.
As a result of this analysis, two patients in the Tagriso group (3%) and 13 patients (20%) in the standard treatment group showed low progression of the central nervous system regardless of the presence or absence of metastasis to the central nervous system.
Professor Sangwi Kim of the Department of Oncology, Asan Medical Center in Seoul said, “It is an encouraging result in EGFR-mutant non-small cell lung cancer that 20% of patients were continuing the first-line treatment of Tagriso at the time of three years of treatment. As the only EGFR TKI that has proven to survive more than 3 years in patients, the clinical results of this FLAURA Chinese will be an opportunity to further solidify the clinical value and justification for use of Tagriso as a first-line treatment.”
Reporter Moon Se-young [email protected]
Copyrightⓒ’Honest Knowledge for Health’ Comedy.com (http://kormedi.com) / Unauthorized reproduction-redistribution prohibited
Source: 코메디닷컴 by kormedi.com.
*The article has been translated based on the content of 코메디닷컴 by kormedi.com. If there is any problem regarding the content, copyright, please leave a report below the article. We will try to process as quickly as possible to protect the rights of the author. Thank you very much!
*We just want readers to access information more quickly and easily with other multilingual content, instead of information only available in a certain language.
*We always respect the copyright of the content of the author and always include the original link of the source article.If the author disagrees, just leave the report below the article, the article will be edited or deleted at the request of the author. Thanks very much! Best regards!